Author

S. Zens

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

R. Offringa· 2 shared A. Arnold· 1 shared A. Bury· 1 shared B. Casati· 1 shared C. Woelfel· 1 shared E. Fakhr· 1 shared E. Huduti· 1 shared E. Ruppin· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

R. Offringa

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Employing RNA editing to engineer personalized tumor-specific neoantigens (editopes)

R. Pecori, B. Casati, R. Merdler-Rabinowicz, N. Landesman, K. Sanghvi, S. Zens, K. Kipfstuhl, V. Pinamonti, A. Arnold, J. M. Lindner, M. Platten, R. Offringa, R. Carretero, E. Ruppin, E. Y. Levanon, F. N. Papavasiliou

This paper develops a method to generate tumor-specific neoantigens using RNA editing, demonstrating its ability to create immunogenic epitopes that activate T cells and enhance immunotherapy potential.

The EMBO Journal · Aug 14, 2026Peer-reviewedCancer Biology

Incorporation of TRDV segments into TCR alpha chains

M. Volkmar, E. Fakhr, S. Zens, R. Offringa, A. Bury, J. Gordon, E. Huduti, T. Woelfel, C. Woelfel

The paper identifies TRDV segments incorporated into TCR alpha chains in human and murine tumor models and shows their prevalence in 10X VDJ datasets.

bioRxiv · Feb 26, 2023 · PreprintImmunology